GenSight Biologics
GenSight Biologics develops gene therapies for neurodegenerative ophthalmic diseases, specifically targeting blindness. The company utilizes Mitochondrial Targeting Sequence and optogenetics technologies to treat conditions such as Leber Hereditary Optic Neuropathy and Retinitis Pigmentosa. Their clinical pipeline includes lenadogene nolparvovec, which is completing development, and the PIONEER Phase I/II trial for GS030.
Biotechnology
Gene Therapy
Healthcare
Funding summary
- Total raised
- €87.7M
- Funding rounds
- 4
Investors in GenSight Biologics
Investors on record for GenSight Biologics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like GenSight Biologics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors